Please use this identifier to cite or link to this item: https://doi.org/10.3390/cancers12092572
DC FieldValue
dc.titleTranscriptional spatial profiling of cancer tissues in the era of immunotherapy: The potential and promise
dc.contributor.authorNerurkar, S.N.
dc.contributor.authorGoh, D.
dc.contributor.authorCheung, C.C.L.
dc.contributor.authorNga, P.Q.Y.
dc.contributor.authorLim, J.C.T.
dc.contributor.authorYeong, J.P.S.
dc.date.accessioned2021-08-23T09:08:48Z
dc.date.available2021-08-23T09:08:48Z
dc.date.issued2020
dc.identifier.citationNerurkar, S.N., Goh, D., Cheung, C.C.L., Nga, P.Q.Y., Lim, J.C.T., Yeong, J.P.S. (2020). Transcriptional spatial profiling of cancer tissues in the era of immunotherapy: The potential and promise. Cancers 12 (9) : 1-20. ScholarBank@NUS Repository. https://doi.org/10.3390/cancers12092572
dc.identifier.issn20726694
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/198839
dc.description.abstractIntratumoral heterogeneity poses a major challenge to making an accurate diagnosis and establishing personalized treatment strategies for cancer patients. Moreover, this heterogeneity might underlie treatment resistance, disease progression, and cancer relapse. For example, while immunotherapies can confer a high success rate, selective pressures coupled with dynamic evolution within a tumour can drive the emergence of drug-resistant clones that allow tumours to persist in certain patients. To improve immunotherapy efficacy, researchers have used transcriptional spatial profiling techniques to identify and subsequently block the source of tumour heterogeneity. In this review, we describe and assess the different technologies available for such profiling within a cancer tissue. We first outline two well-known approaches, in situ hybridization and digital spatial profiling. Then, we highlight the features of an emerging technology known as Visium Spatial Gene Expression Solution. Visium generates quantitative gene expression data and maps them to the tissue architecture. By retaining spatial information, we are well positioned to identify novel biomarkers and perform computational analyses that might inform on novel combinatorial immunotherapies. @ 2020 by the authors. Licensee MDPI, Basel, Switzerland.
dc.publisherMDPI AG
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScopus OA2020
dc.subjectBiomarkers
dc.subjectCancer
dc.subjectClonal diversity
dc.subjectDigital spatial profiling
dc.subjectHeterogeneity
dc.subjectImmunotherapy
dc.subjectIn situ hybridization
dc.subjectTranscriptomics
dc.typeReview
dc.contributor.departmentYONG LOO LIN SCHOOL OF MEDICINE
dc.description.doi10.3390/cancers12092572
dc.description.sourcetitleCancers
dc.description.volume12
dc.description.issue9
dc.description.page1-20
Appears in Collections:Students Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3390_cancers12092572.pdf2.23 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons